NSCLC: Atezolizumab Improves Survival Compared With Docetaxel

Atezolizumab significantly improved overall survival compared with docetaxel and was well tolerated in non-small cell lung cancer.
Atezolizumab significantly improved overall survival compared with docetaxel and was well tolerated in non-small cell lung cancer.

Atezolizumab significantly improved overall survival compared with docetaxel and was well tolerated in patients with previously treated non-small cell lung cancer (NSCLC), a study published in the journal The Lancet has shown.1

For the international, open-label, phase 2 study, researchers enrolled 144 patients with NSCLC who progressed on postplatinum chemotherapy. Patients were randomly assigned 1:1 to receive atezolizumab 1200 mg IV or docetaxel 75 mg/m2 IV once every 3 weeks. In addition to evaluating the safety and efficacy of this immunotherapeutic agent, researchers sought to analyze whether baseline PD-L1 expression of tumor cells and tumor-infiltrating immune cells is a prognostic marker.

Results showed that median overall survival was 12.6 months (95% CI: 9.7-16.4) with atezolizumab compared with 9.7 months (95% CI: 8.6-12.0) with docetaxel (HR, 0.73; 95% CI: 0.53-0.99; P=.04).

Further, researchers found that improvement in survival correlated with PD-L1 immunohistochemistry expression on tumor cells and tumor-infiltrating immune cells. This suggests that PD-L1 expression is predictive for atezolizumab benefit.

The study also demonstrated that patients with preexisting immunity, defined by high T-effector–interferon-γ-associated gene expression, had improved overall survival with atezolizumab.

In terms of safety, 8% of patients receiving atezolizumab discontinued treatment due to adverse events compared with 22% of patients in the docetaxel arm. Eleven percent and 39% of patients in the atezolizumab and docetaxel groups, respectively, experienced treatment-related grade 3 to 4 adverse events.

Of note, 1 patient in the atezolizumab group and 3 in the docetaxel group died as a result of a treatment-related adverse event.

REFERENCE

1. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [published online ahead of print March 9, 2016]. Lancet. doi:10.1016/S0140-6736(16)00587-0.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs